Boehringer Ingelheim Launches Dabigatran In Japan
This article was originally published in PharmAsia News
Executive Summary
Nippon Boehringer Ingelheim launched Pradaxa (dabigatran) in Japan for atrial fibrillation and preventing the onset of strokes